- CIGNA ( NYSE: CI ): Q3 Non-GAAP EPS of $4.96 beats by $0.09 .
- Revenue of $45.75B (+0.2% Y/Y) in-line.
- The Cigna Healthcare MCR of 84.0% for fourth quarter 2022 compares to 87.0% for fourth quarter 2021, reflecting lower direct COVID-19 costs and improved stop-loss results. The fourth quarter 2022 MCR also benefited from effective execution in pricing and affordability initiatives.
- Cigna's outlook for full year 2023 adjusted revenues is projected to be at least $187.0 billion vs $190.20B consensus. Cigna’s outlook for full year 2023 consolidated adjusted income from operations is projected to be at least $7.33 billion, or at least $24.60 per share vs $24.80 consensus.
- Total customer relationships at the end of 2022 grew by 2% to 189.7 million.
- Total pharmacy customer base in 2022 decreased by 2% to 105.6 million due to client attrition in early 2022.
- The total medical customer base at the end of 2022 grew 5% to 18.0 million, an increase of 923,000 customers from December 31, 2021, primarily driven by growth in U.S. Commercial, partially offset by a decrease in U.S. Government inclusive of the divestiture of the Medicaid business.
For further details see:
CIGNA Non-GAAP EPS of $4.96 beats by $0.09, revenue of $45.75B in-line, 2023 outlook below estimates